

Scott Letendre, M.D.

Curriculum Vitae

March 1, 2008

PERSONAL INFORMATION

Present Position Associate Professor of Medicine
University of California, San Diego

Office HIV Neurobehavioral Research Center and
Antiviral Research Center
150 West Washington Street
San Diego, California 92103
Telephone: (619) 543-8080
Fax: (619) 298-0177

Electronic Mail sletendre@ucsd.edu

Citizenship United States of America

EDUCATION

Clinical Research Training University of California, San Diego, CREST Program, 2000-2.

Research Fellowship University of California, San Diego, NeuroAIDS, 1997-9.

Biometry Training Duke University; Biometry Training Program, 1995-6.

Fellowship Duke University; Durham, NC; Infectious Disease, 1994-7.

Chief Residency Naval Medical Center; San Diego, CA; 1993-4.

Residency Naval Medical Center; San Diego, CA; Internal Medicine, 1990-2.

Tropical Medicine Naval Tropical Medicine School; San Juan, Puerto Rico; 1989.

Internship Naval Hospital; Oakland, CA; Internal Medicine, 1986-7.

Medical School Georgetown University; Washington, DC, M.D., 1986.

University University of Notre Dame du Lac; Notre Dame, IN; B.S., 1982.

BOARD CERTIFICATION AND LICENSURE

Infectious Disease American Board of Internal Medicine, 1997.

Internal Medicine American Board of Internal Medicine, 1993.

California License Number A063591, 1997-Present.

North Carolina License Number 94-00895, 1994-8.

District of Columbia License Number 17952, 1989-94.

Federal Licensing Federal Licensing Examination, 1988.

PROFESSIONAL APPOINTMENTS

2006 – Present Associate Professor of Medicine, UCSD.

2000 – 2006 Assistant Professor of Medicine, UCSD.

1996 – 1997 Clinical Research Collaborator, Glaxo Wellcome,
Virology Laboratory, Research Triangle Park, NC.

1995 – 1997 Health Services Research Fellow, Veterans' Administration
Medical Center, Durham, NC.

1993 – 1994 CME Coordinator, Naval Medical Center, San Diego.

1993 – 1994 Ward Medical Officer, Naval Medical Center, San Diego.

1993 – 1994 Clinical Instructor, University of California, San Diego.

1992 – 1994 Staff Internist, Naval Medical Center, San Diego.

HONORS, AWARDS, AND PROFESSIONAL SOCIETIES

2001	Junior Faculty Mentoring Fellowship, National Center for Leadership in Academic Medicine, UCSD.
1999	Fellow Travel Grant, Sixth Conference on Retroviruses and Opportunistic Infections.
1996	Fellow Travel Grant, Society for Healthcare Epidemiology of America.
1993, 1994	U.S. Navy Achievement Medals.
1985	Selection for Refugee Medicine Rotation, Site 2, Thailand.
1982 – 1986	U.S. Navy Health Professions Scholar.
1978 – 1982	Gore Family Memorial Foundation Scholar.
1999 – Present	Member, International Society of Neurovirology.
1995 – Present	Member, American Society for Microbiology.
1994 – Present	Member, Infectious Disease Society of America.
1990 – Present	Member, American College of Physicians.

COMMITTEE AND ADMINISTRATIVE SERVICE

2007 – Present	Organizing Committee, 8th International Symposium on NeuroVirology.
2007 – Present	Co-Director, AIDS Clinical Rounds, UCSD Antiviral Research Center.
2006 – Present	Infection Control Committee, UCSD Medical Center.
2004 – Present	Neurology Subcommittee (ad hoc member), AIDS Clinical Trials Group.
2004 – Present	Neurologic AIDS Research Consortium CNS Focus Group, AIDS Clinical Trials Group.
2004 – Present	Recruitment and Admissions Committee, UCSD.
2003 – 2004	Chair, Neurology-Liver Disease Focus Group, AIDS Clinical Trials Group.
2003 – 2004	Division Coordinator, UCSD SOM Independent Study Projects.
2001 – 2004	Pharmacy and Therapeutics Committee, UCSD Medical Center.
2000 – Present	Internal Medicine Residency Candidate Interviewer, UCSD.
2000 – Present	Adverse Events Reviewer, UCSD Antiviral Research Center.

TEACHING ACTIVITIES

2007 – Present	Lecturer, UCSD SPPS Microbiology Course.
2006 – Present	Lecturer, UCSD SOM Microbiology Course.
2004 – Present	Lecturer, Masters in Advanced Studies Program, UCSD.
2002 – Present	Independent Study Project Advisory Board, UCSD.
2000 – 2001	Introduction to Clinical Medicine, UCSD.
1998 – 2000	Infectious Disease Journal Club Coordinator, UCSD.
1994 – 1997	Lecturer, Infectious Diseases Clinical Service, Duke University.
1994 – 1995	Lecturer, Cabarrus Medical Center, Concord, NC.
1991 – 1992	Lecturer, M.P.H. Program, San Diego State University.

FUNDING SOURCES

2005 – Present	Principal Investigator, Project 5, Program Project, NIDA.
2002 – Present	Core Principal Investigator, CHARTER, NIMH and NINDS.
2002 – 2006	Principal Investigator, R01 Project Award, NIDA.
1999 – 2004	Principal Investigator, K23 Research Career Award, NIMH.
1998 – Present	Co-Investigator, R01 Project Award, NIMH.

COMMUNITY SERVICE

1997 – 2005	AIDS Clinical Trials Group, Community Advisory Board, UCSD.
1995 – 1997	AIDS Clinical Trials Group, Community Advisory Board, Duke.
1994 – 1995	Duke Outreach Program, Cabarrus Medical Center, Concord, NC.

MILITARY SERVICE

1986 – 1994	Lieutenant Commander, U.S. Navy.
1988 – 1990	Flight Surgeon, Second Marine Aircraft Wing, Cherry Point, NC.
1989	Tropical Medicine Course, San Juan, Puerto Rico.
1989	Cold Weather Medicine Course, Bridgeport, CA.
1988 – 1989	Wing Medical Officer, NATO Cold Weather Exercises, Norway.
1987 – 1988	Aviation Medicine Course, Naval Aerospace Medicine Institute.

RESEARCH INTERESTS

Dr. Letendre's research focuses on patient-oriented investigations of the correlates and consequences of chronic central nervous system infections, primarily HIV and HCV. In collaboration with the UCSD HIV Neurobehavioral Research Center, Dr. Letendre conducts treatment trials of neurocognitively impaired HIV-infected individuals and analyzes their response to therapy, the pharmacokinetics of antiretrovirals, and the CSF concentrations of biomarkers. In collaboration with the UCSD Antiviral Research Center, he conducts HIV treatment trials of investigational and FDA-approved medications.

PEER REVIEWER

AIDS.
AIDS Research and Human Retroviruses.
American Journal of Psychiatry.
Antiviral Therapy.
Clinical Infectious Diseases.
Drug Safety.
Journal of Acquired Immune Deficiency Syndromes.
Journal of Infectious Diseases.
Journal of the International Neuropsychological Society.
Journal of Neuroimmune Pharmacology.
The Lancet Neurology.
Neurology.
PLoS Medicine.

PUBLICATIONS

1. **Letendre SL**, Lanier ER, McCutchan JA. Cerebrospinal fluid β chemokine concentrations in neurocognitively impaired individuals infected with human immunodeficiency virus type 1. *J Infect Dis*, 180:310-319, 1999.
2. **Letendre S**, Capparelli E, Ellis R, McCutchan J, and the HIV Neurobehavioral Research Center Group. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. *Antimicrob Agents Chemother*, 44(8):2173-2175, 2000.

3. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, **Letendre S**, Grant I, and the HNRC Group. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. *AIDS*, 15(14):1898-1899, 2001.
4. Smith D, **Letendre SL**. Viral pneumonia as a serious complication of etanercept therapy. *Ann Intern Med*, 136(2):174, 2002.
5. Langford TD, **Letendre SL (co-first author)**, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T, Masliah E, and the HNRC Group. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. *AIDS*, 16(7):1019-1029, 2002.
6. Ellis RJ, Moore DJ, Childers ME, **Letendre S**, McCutchan JA, Wolfson T, Spector SA, Hsia K, Heaton RK, Grant I, for the HNRC Group. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. *Arch Neurol*, 59(6):923-928, 2002.
7. Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, **Letendre S**, Cohen BA, Marder K, Ellis RJ, Marra CM, and the Neurologic AIDS Research Consortium. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. *Neurology*, 59:1568-1573, 2002.
8. Blanchard JN, Powell HC, Freeman WR, **Letendre S**, Blanchard D, Shimizu C, Burns JC. Recurrent Kawasaki disease-like syndrome in a patient with acquired immunodeficiency syndrome. *Clin Infect Dis*, 36:105-111, 2003.
9. Gonzalez R, Heaton RK, Moore DJ, **Letendre S**, Ellis RJ, Wolfson T, Marcotte T, Cherner M, Rippeth J, Grant I, and the HNRC Group. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. *J Int Neuropsychol Soc*, 9(1):64-71, 2003.
10. Langford TD, **Letendre SL**, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. *Brain Pathol*, 13:195-210, 2003.
11. Chardos JF, Smith D, **Letendre S**. Demyelinating encephalitis (photo quiz). *Clin Infect Dis*, 36(10):1266-1267 and 1332-1334, 2003.
12. Marcotte TD, Deutsch R, McCutchan JA, Moore DJ, **Letendre S**, Ellis RJ, Wallace MR, Heaton RK, Grant I, for the San Diego HIV Neurobehavioral Research Center (HNRC) Group. Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. *Arch Neurol*, 60:1406-1412, 2003.
13. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, **Letendre S**, Grant I; HIV Neurobehavioral Research Center Group. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. *J Infect Dis*, 188(12):1820-1826, 2003.
14. Taylor MJ, **Letendre SL**, Schweinsburg BC, Alhassoon OM, Brown GG, Gongvatana A, Grant I, and the HNRC. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. *J Int Neuropsychol Soc*, 10(1):110-3, 2004.
15. **Letendre SL**, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, Heaton RK, Grant I, Ellis RJ, and the HNRC Group. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. *Ann Neurol*, 56(3):416-23, 2004.

16. Singh KK, Ellis RJ, Marquie-Beck J, **Letendre S**, Heaton RK, Grant I, Spector SA. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. *J Neuroimmunol*, 157(1-2):185-92, 2004.
17. **Letendre S**, Marquie-Beck J, Singh KK, de Almeida S, Zimmerman J, Spector SA, Grant I, Ellis R; the HNRC Group. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. *J Neuroimmunol*, 157(1-2):193-196, 2004.
18. Strain MC, **Letendre S**, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, Marquie-Beck J, Durelle J, Grant I, Richman DD, Marcotte T, McCutchan JA, Ellis RJ, Wong JK. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. *J Virol*, 79(3):1772-1788, 2005.
19. **Letendre SL**. The effects of antiretroviral therapy on viral and nonviral markers in cerebrospinal fluid. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, eds. *The Neurology of AIDS*. 2nd ed. New York, NY: Oxford University Press, 617-627, 2005.
20. McCutchan JA, **Letendre SL**. Pharmacology of antiretroviral drugs in the central nervous system: pharmacokinetics, antiretroviral resistance, and pharmacodynamics. In: Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S, eds. *The Neurology of AIDS*. 2nd ed. New York, NY: Oxford University Press, 729-734, 2005.
21. Cherner M, **Letendre S**, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, Grant I, and the HIV Neurobehavioral Research Group. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. *Neurology*, 64(8):1343-1347, 2005.
22. Capparelli E, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, van den Brande G, Ellis R, **Letendre S**, and the HNRC Group. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. *AIDS*, 19(9):949-952, 2005.
23. Capparelli EV, **Letendre SL**, Ellis RJ, Patel P, Holland D, McCutchan JA. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. *Antimicrob Agents Chemother*, 49(6):2504-2506, 2005.
24. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, **Letendre S**, Videen JS, McCutchan JA, Patterson TL, Grant I, and the HNRC Group. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. *J Neurovirol*, 11(4):356-364, 2005.
25. **Letendre S**. Methamphetamine, HIV, and the human brain. *The PRN Notebook*, 10(3):13-17, 2005.
26. **Letendre SL**, Cherner M, Ellis RJ, Gragg B, Marquie-Beck J, Gragg B, Marcotte T, Heaton RK, McCutchan JA, Grant I, and the HNRC Group. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. *AIDS*, 19(Suppl 3):S72-S78, 2005.
27. de Almeida SM, **Letendre S**, Zimmerman J, Lazzaretto D, McCutchan A, Ellis R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. *J Neuroimmunol*, 169(1-2):144-152, 2005.
28. Marcotte TD, Lazzaretto D, Scott JC, Roberts E, Woods SP, **Letendre S**, and the HNRC Group. Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. *J Clin Exp Neuropsychol*, 28(1):13-28, 2006.

29. de Almeida SM, **Letendre S**, Ellis R. Human immunodeficiency virus and the central nervous system. *Braz J Infect Dis*, 10(1):41-50, 2006.
30. **Letendre S**, Ellis RJ. Neurologic complications of HIV disease and their treatments. *Top HIV Med*, 14(1):21-26, 2006.
31. Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, **Letendre S**, Grant I, McCutchan JA, Masliah E, Ellis RJ, and the HIV Neurobehavioral Research Center (HNRC) Group. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. *J Neurovirol*, 12(2):100-107, 2006.
32. Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, **Letendre S**, Smith DM, Gunthard HF, Grant I, Marcotte TD, McCutchan JA, Richman DD, Wong JK. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. *Brain*, 129(7):1872-1883, 2006.
33. **Letendre SL**, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, Durelle J, Grant I, Everall I, and the HNRC Group. Lithium improves HIV-associated neurocognitive impairment. *AIDS*, 20(14):1885-1888, 2006.
34. Monteiro de Almeida S, **Letendre S**, Zimmerman J, Kolakowski S, Lazzaretto D, McCutchan JA, Ellis R. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. *J Neuroimmunol*, 179(1-2):180-185, 2006.
35. Ances BM, **Letendre S**, Buzzell M, Marquie-Beck J, Lazzaretto D, Marcotte TD, Grant I, Ellis RJ, and the HNRC Group. Valproic acid does not affect markers of human immunodeficiency virus disease progression. *J Neurovirol*, 12(5):403-406, 2006.
36. Woods SP, Morgan EE, Marquie Beck J, Carey CL, Grant I, **Letendre SL**, and The HIV Neurobehavioral Research Center (HNRC) Group. Markers of macrophage activation and axonal injury are associated with prospective memory in HIV-1 disease. *Cogn Behav Neurol*, 19(4):217-221, 2006.
37. McArthur JC, **Letendre SL**. Is the glass three-quarters full or one-quarter empty? *J Infect Dis*, 194(12):1628-1631, 2006.
38. May S, **Letendre S**, Haubrich R, McCutchan JA, Heaton R, Capparelli E, Ellis R. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in NeuroAIDS. *J Neuroimmune Pharmacol*, 2(1):97-104, 2007.
39. **Letendre SL**, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I, The CHARTER Group. The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. *J Neuroimmune Pharmacol*, 2(1):120-127, 2007.
40. Woods SP, Carey CL, Moran LM, Dawson MS, **Letendre SL**, Grant I, the HIV Neurobehavioral Research Center (HNRC) Group. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. *Arch Clin Neuropsychol*, 22(2):187-195, 2007.
41. Taylor MJ, Schweinsburg BC, Alhassoon OM, Gongvatana A, Brown GG, Young-Casey C, **Letendre SL**, Grant I, and the HNRC Group. Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. *J Neurovirol*, 13(2):150-159, 2007.

42. **Letendre S**, Ances B, Gibson S, Ellis RJ. Neurologic complications of HIV disease and their treatment. *Top HIV Med*, 15(2):32-39, 2007.
43. **Letendre S**, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, Heaton R, Ellis R, Everall IP, Grant I, Masliah E, HIV Neurobehavioral Research Center Group. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. *J Infect Dis*, 196(3):361-370, 2007.
44. Podzamczar D, King MS, Klein CE, Flexner C, Katlama C, Havlir DV, **Letendre SL**, Eron JJ, Brun SC, Bernstein B. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. *HIV Clin Trials*, 8(4):193-204, 2007.
45. Cysique LA, Jin H, Franklin Jr. DR, Morgan EE, Shi C, Yu X, Wu Z, Taylor MJ, Marcotte TD, **Letendre S**, Ake C, Grant I, Heaton RK, and the HNRC Group. Neurobehavioral effects of HIV-1 infection in China and the United States: a pilot study. *J Int Neuropsychol Soc*, 13(5):781-90, 2007.
46. Vigil O, Woods SP, Moran LM, **Letendre SL**, Young-Casey C, Grant I, Atkinson JH, for the HIV Neurobehavioral Research Center (HNRC) Group. Is Hepatitis C infection associated with increased risk of depression in persons with methamphetamine dependence? *Am J Addict*, 16(5):418-423, 2007.
47. Cachay ER, Moini N, Kosakovsky Pond SL, Pesano R, Lie YS, Aiem H, Butler DM, **Letendre S**, Mathews WC, Smith DM. Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. *The Open AIDS Journal*, 1:5-10, 2007.
48. **Letendre SL**, van den Brande G, Hermes A, Woods SP, Durelle J, Beck JM, McCutchan JA, Okamoto C, Ellis RJ, and the HIV Neurobehavioral Research Center Group. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. *Clin Infect Dis*, 45(11):1511-1517, 2007.
49. Huang JS, **Letendre S**, Marquie-Beck J, Cherner M, McCutchan JA, Grant I, Ellis R. Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. *J Neuroimmune Pharmacol*, 2(4):352-358, 2007.
50. **Letendre S**, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol*, 65(1):65-70, 2008.
51. Brew BJ, **Letendre SL**. Biomarkers of HIV related central nervous system disease. *Int Rev Psychiatry*, 20(1):73-88, 2008.
52. Ances BM, **Letendre SL**, Alexander T, Ellis RJ. Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. *Int Rev Psychiatry*, 20(1): 89-93, 2008.
53. Woods SP, Carey CL, Iudicello JE, **Letendre SL**, Grant I. Neuropsychological aspects of HIV infection. In: Grant I, Adams KM, eds. *Neuropsychological Assessment of Neuropsychiatric Disorders*. 3rd ed. New York, NY: Oxford University Press. In press.
54. Vigil O, Posada C, Woods SP, Atkinson JH, Heaton RK, Perry W, Hassanein TI, Grant I, **Letendre SL**, and the HIV Neurobehavioral Research Center (HNRC) Group. Motor and psychomotor impairments predict dependence in everyday functioning in hepatitis C infection. *J Clin Exp Neuropsychol*. Submitted.

55. Cherner M, Young C, Deiss R, Suarez P, **Letendre S**, Marcotte T, Atkinson J, Grant I, Heaton R. Neuropsychological effects of prior methamphetamine use in currently abstinent, dependent adults. *J Psychiatry Neurosci*. Submitted.

PUBLISHED ABSTRACTS

1. **Letendre SL**, Ellis RJ, Heaton RK, Atkinson JH, Grant I, McCutchan JA. The cognitive intervention trial: the effects of maximal antiretroviral therapy on CSF HIV RNA levels and HIV-1 associated neurocognitive disorder. *J Neurovirol*, 4(3):357, 1998.
2. Wong JK, Gunthard H, Ellis RE, **Letendre S**, Kee K, Denison B, Hsia K, Spector S, Grant I, Richman DD, McCutchan JA. The development and trafficking of multi-drug resistant HIV in plasma and CSF during the failure of combination antiviral therapy. *Antivir Ther*, 4(Suppl 1):76, 1999.
3. Ellis RJ, McCutchan JA, Heaton RK, **Letendre SL**, Spector SA, Marcotte TD, Hsia K, Dawson LK, Cherner M, Grant I. Elevated HIV RNA levels in cerebrospinal fluid predict increased subsequent risk for the development of neurocognitive disorders. *Neurology*, 52(Suppl 2):253, 1999.
4. **Letendre SL**, Ellis RJ, Rippeth J, McCutchan JA, and the HNRC Group. Reduction of CSF HIV RNA correlates with reversal of HIV-induced cognitive dysfunction. *J Neurovirol*, 6(3):246, 2000.
5. Ellis RJ, **Letendre SL**, Deutsch R, Hsia K, Spector SA, McCutchan JA, and the HNRC Group. Demonstration of a different "set point" for HIV RNA in CSF, as compared to plasma. *J Neurovirol*, 6(3):256, 2000.
6. **Letendre S**, Cherner M, Ellis R, Marcotte T, Heaton R, McCutchan JA, Grant I. Individuals co-infected with hepatitis C (HCV) and HIV are more cognitively impaired than those infected with either virus alone. *J Neurovirol*, 8(Suppl 1):14, 2002. Abstract 27.
7. Marcotte TD, Coleman RD, Heaton RK, Rivera-Mindt M, McCutchan JA, **Letendre S**, Ellis RJ, Roberts E, Grant I. Virologic and neuropsychologic predictors of driving ability in HIV infection. *J Neurovirol*, 8(Suppl 1), 2002. Abstract 60.
8. Rivera Mindt M, **Letendre S**, Cherner M, Langford T, Masliah E, Heaton R, Jernigan T, Marcotte T, Grant I. A case study of HIV encephalitis: the utility of neuropsychologic (NP), neuromedical (NM), and neuroimaging (NI) evaluations in detecting early HIV brain involvement. *J Neurovirol*, 8(Suppl 1), 2002. Abstract 148.
9. **Letendre SL**, Paxinos E, Wong J, Petropoulos C, Whitcomb J, Galovich J, Hellmann N, McCutchan JA, Ellis RJ. Divergent evolution of phenotypic antiretroviral susceptibility of HIV isolated from cerebrospinal fluid and plasma. *Antivir Ther*, 7(Suppl 1):S73, 2002. Abstract 66.
10. Woods SP, Morgan EE, Marquie-Beck J, Carey CL, Grant I, **Letendre SL**, the HNRC Group. Neuropathogenesis of prospective memory impairment in HIV-1 infection. *Clin Neuropsychol*, 19:563-564, 2005. Abstract.
11. Woods SP, Iudicello JD, Dawson MS, Moran LM, Carey CL, **Letendre SL**, Grant I. HIV-associated prospective memory deficits predict functional dependence. *Clin Neuropsychol*, 21:701, 2007. Abstract.
12. Vigil O, Posada C, Woods SP, Atkinson JH, Heaton RK, Perry W, Hassanein TI, Grant I, **Letendre SL**, and the HNRC Group. Cognitive impairment predicts functional declines in hepatitis C infection. *Clin Neuropsychol*, 21:702, 2007. Abstract.

13. Hightower GK, **Letendre SL**, Cachay ER, Cherner M, Gibson S, Ellis R, Richman DD, Ignacio CC, Smith DM. Antiretroviral resistance and neuropsychological performance among HIV-infected individuals. *Antivir Ther* 12(Suppl 1):S119, 2007. Abstract 108.

RECENT PRESENTED ABSTRACTS

1. Jacobsen MW, Archibald SL, Fennema-Notestine C, Ellis R, **Letendre S**, Ances B, Lansing A, Grant I, Jernigan TL. Higher HIV RNA in cerebrospinal fluid is associated with greater activation on fMRI. 58th Annual Meeting of the American Academy of Neurology (AAN); April 1-8, 2006; San Diego, CA. Abstract P03.147.
2. **Letendre S**, McClernon D, Benjamin R, Clifford D, Collier A, Gelman B, McArthur J, McCutchan J, Morgello S, Ellis R, and the CHARTER Group. Presence of HIV RNA in cerebrospinal fluid that is undetectable with the ultrasensitive assay. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 369.
3. Yeh RF, **S Letendre**, Novak I, Lipman B, Hermes A, Mayberry C, Miguel B, Nemecek J, Norton M, Gathe Jr. J. Single agent therapy with lopinavir/ritonavir controls HIV-1 viral replication in the central nervous system. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 381.
4. Jernigan T, **Letendre S**, Archibald S, Clifford D, Collier A, Gelman B, McArthur J, McCutchan J, Morgello S, Ellis R, and the CHARTER Group. Chemokines in CSF are associated with white matter and cortical gray matter volumes in HIV-infected individuals. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 370.
5. Best BM, **Letendre S**, Rossi S, Clifford D, Collier A, Gelman B, McArthur J, McCutchan J, Morgello S, Ellis R. Low exposure to paroxetine and sertraline, but not to citalopram, escitalopram and fluoxetine in HIV-infected patients. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 574.
6. Marra C, Sinha S, Clifford D, Evans S, **Letendre S**, Ellis R, Aweeka F, Schifitto G, Coombs R, Robertson K, and the Adult AIDS Clinical Trials Group 736 Team. Suppression of HIV replication in plasma requires suppression of HIV replication in cerebrospinal fluid. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 382b.
7. **Letendre S**, Marquie-Beck J, Clifford D, Collier A, Gelman B, McArthur J, McCutchan J, Simpson D, Grant I, Ellis R, and the CHARTER Group. Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 384.
8. Hightower GK, **Letendre SL**, Cherner M, Gibson S, Ellis R, Ignacio CC, Heaton R, Richman DD, Smith DM. Antiretroviral resistance influences CSF HIV RNA levels and neuropsychological performance in HIV-infected individuals. 8th International Symposium on NeuroVirology; October 29-November 2, 2007; San Diego, CA.
9. Everall I, Vada F, **Letendre S**, Lazzaretto D, Gelman B, Morgello S, Singer E, Ellis R, Masliah E, Grant I, and National NeuroAIDS Tissue Consortium and the UCSD HIV Neurobehavioral Research Center. Reducing the prevalence of primary HIV brain pathology by antiretrovirals. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA.

Abstract 67.

10. **Letendre S**, Ellis R, Cysique L, Cherner M, Gibson S, Heaton R, McCutchan A, and the HNRC Group. Low-grade immune restoration disease may limit recovery from HIV-associated neurocognitive impairment. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 68.
11. Best B, **Letendre S**, Koopmans P, Clifford D, Collier A, Gelman B, McArthur J, Simpson D, Capparelli E, Ellis R, and the CHARTER Group. Low tenofovir concentrations in cerebrospinal fluid. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 131.
12. Hightower G, **Letendre S**, Cherner M, Gibson S, Ellis R, Ignacio C, Heaton R, Grant I, Richman D, Smith D, and San Diego HIV Neurobehavioral Research Center (HNRC) group. ART resistance influences CSF HIV RNA levels and neuropsychological performance in HIV-infected individuals. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 394.
13. **Letendre S**, Cysique L, Shi C, Yu X, Hong K, Wu Z, Ake C, Jin H, Grant I, Heaton R, and the HNRC Group. HIV and HCV are associated with worse neuropsychological performance in Anhui, China. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 413.
14. Bousman C, Cherner M, Mausbach B, Atkinson H, Everall I, **Letendre S**, Patterson T, Grant I, and the HNRC group. Mood and sexual behavior profiles of men who have sex with men in the context of methamphetamine and HIV. 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 547.